Pharmacokinetics of calcium antagonists.
Calcium antagonists are a biochemically heterogeneous group of drugs that share the property of blocking the entry of calcium into cells by voltage-operated channels in cardiac and smooth muscle. They are useful in the management of angina pectoris and hypertension. The drugs available at present include nifedipine, verapamil, and diltiazem. All three drugs have similar pharmacokinetic properties of low and variable bioavailability, high first-pass metabolism, short elimination half-life, and active metabolites. The pharmacokinetics of calcium antagonists are relevant, because in individual patients the intensity and duration of the pharmacological effect is related to the level of drug in plasma. Amlodipine is a new dihydropyridine calcium antagonist in advanced clinical development. It has a completely different pharmacokinetic profile. It is water soluble and photostable, and has a long half-life of 35-50 h. Amlodipine is slowly absorbed, its absolute bioavailability is high, and it is extensively metabolized in the liver. The long half-life is associated with a prolonged (greater than 24 h) duration of pharmacodynamic action. Amlodipine, because of its novel pharmacokinetics, may offer practical advantages over existing calcium antagonists in the long-term treatment of cardiovascular disease.
Reid
J L
JL
University Department of Materia Medica, Stobhill Hospital, Glasgow, Scotland.
Meredith
P A
PA
Donnelly
R
R
Elliott
H L
HL
D002121:Calcium Channel Blockers / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy; D006801:Humans
D002121:Calcium Channel Blockers